Eli Lilly beats EPS $8.55

Eli Lilly’s quarter was basically a reminder that this is no longer just a “hot weight-loss drug” story. It is now a scale story. The company reported first-quarter 2026 non-GAAP EPS of $8.55 on April 30, with revenue up 56% to $19.8 billion, and then raised its full-year outlook. That is the kind of beat that tells you the business is getting more efficient as it gets bigger — not less. What powered the quarter? The short answer is Mounjaro and Zepbound. Lilly said the quarter was driven mainly by volume growth, and the call made the picture even clearer: Mounjaro and Zepbound together produced $12.8 billion in global revenue. That is an enormous number for one drug franchise, and it helps explain why overall revenue grew much faster than most large drug companies can manage. Does volume matter more than price here? Because Lilly is selling into a market that has been constrained by supply, access, and launch timing — not by lack of demand. The press release said revenue growth came from a 65% increase in volume, partly offset by a 13% hit from lower realized prices. On the call, management also flagged a U.S. price decline tied to rebates and discounts. So the story is not “Lilly charged more.” It is “Lilly shipped a lot more.” ### Is this just a U.S. obesity story? No — and that is one of the more important parts of the quarter. Lilly said Mounjaro has now launched in more than 55 countries, and the call highlighted strong positions in markets like Brazil and Korea. International incretin demand is expanding fast, and Lilly is already moving from a U.S.-centric launch story into a global rollout story. That matters because international growth can keep the franchise compounding even if U.S. pricing stays messy. ### Why did profits jump so hard? Scale. Lilly’s non-GAAP performance margin rose to 50%, up about 7 percentage points from a year earlier. That is what operating leverage looks like in plain English — once factories, sales channels, and launch infrastructure are in place, extra revenue starts dropping through more cleanly. The catch is that this only works if Lilly can keep supply flowing and keep enough patients covered by insurers. But this quarter shows the flywheel is starting to spin. ### What changed in guidance? Lilly raised 2026 full-year revenue guidance to $82 billion to $85 billion and lifted non-GAAP EPS guidance to $35.50 to $37.00. Companies do not usually raise guidance this early unless they think demand visibility is real. In Lilly’s case, that confidence seems tied to continued momentum in obesity, diabetes, and the early launch of its oral GLP-1, Foundayo. Foundayo gives Lilly a way to widen the market beyond people willing to start on an injection. Lilly said the FDA approved it in the U.S. and framed it as the only approved GLP-1 pill without food-and-water timing restrictions. On the call, management said more than 20,000 patients had already been treated and that 80% were new to the GLP-1 class. So this is not just product line extension — it may be market expansion. ### What is the real takeaway? Lilly is moving from scarcity to system. The quarter showed a company that can convert huge obesity demand into revenue growth, margin expansion, and higher guidance at the same time. If supply keeps improving and payer access holds, the bigger story is not one earnings beat. It is that Lilly may be building the dominant global GLP-1 platform.